ANHYDRON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Anhydron, and when can generic versions of Anhydron launch?
Anhydron is a drug marketed by Lilly and is included in one NDA.
The generic ingredient in ANHYDRON is cyclothiazide. Additional details are available on the cyclothiazide profile page.
Summary for ANHYDRON
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 57 |
Patent Applications: | 1,230 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ANHYDRON at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ANHYDRON
US Patents and Regulatory Information for ANHYDRON
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lilly | ANHYDRON | cyclothiazide | TABLET;ORAL | 013157-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |